If you have been wondering whether CRISPR Therapeutics at around $57 a share is a bargain or a bubble, you are not alone. This stock sits at the crossroads of high science and high expectations. The ...

This year, gene-editing technology was customized to fix mutations in a single patient’s genes for the first time.

CRISPR Gene editing therapy is used for the first time in living humans with amazing results. Trump is guilty of mortgage ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in ...

Discover how scientists engineered goldenberry plants to grow 35% shorter than usual, making them suitable for large-scale ...

A one-year-old baby boy has received an incredible honour, for helping researchers get one step closer to finding treatment ...

Genetic modification improves environmental credentials of ‘particularly promising’ substitute that outperforms poultry, ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of ...

CRISPR Therapeutics (NASDAQ:CRSP) gains visibility as biotechnology activity aligns with broader movements across the Nasdaq ...

A rare disease mom and scientist shares on the "First Opinion Podcast" how she serves as a translator between her two ...

Bispecific antibodies bring multiple tumor-cell-killing mechanisms into play simultaneously. When a T cell is activated and ...